# Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma

Source: https://onco.cc/trials/nct04733183/  
OnCo record `nct04733183` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Dacarbazine in sarcomas, run by Philogen S.p.A., active and no longer recruiting.

## Summary

Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma is a phase 2 interventional study registered as NCT04733183 by Philogen S.p.A., with 98 participants planned, started 2020-08-28 and due to reach its primary completion in 2025-12. Interventions recorded: Dacarbazine, onfekafusp alfa. Conditions listed: Soft Tissue Sarcoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04733183
- Phase: 2
- Setting: A Randomized Study to Investigate the Efficacy and Safety of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma
- Sponsor: Philogen S.p.A.
- Enrolled: 98

## Sources

- ClinicalTrials.gov NCT04733183: https://clinicaltrials.gov/study/NCT04733183

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- drugs: [Dacarbazine](https://onco.cc/drugs/dacarbazine/)
- companies: [Philogen S.p.A.](https://onco.cc/companies/philogen-s-p-a/)

---
JSON: https://onco.cc/api/v1/entities/nct04733183.json